Colorectal Cancer

Dr. Thejus Jayakrishnan discussed how patients and physicians weigh treatment options in later-line metastatic colorectal cancer.

Patients with stage 3 colorectal cancer who tested MRD-positive with Signatera after surgery saw a meaningful survival benefit from Celebrex plus chemotherapy.

The FDA granted fast track status to muzastotug plus Keytruda for adults with microsatellite stable metastatic colorectal cancer without liver metastases.

Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data presented at the 2025 ESMO Congress.

$100 Million Initiative by Colorectal Cancer Alliance Aims to Accelerate Progress.

After a surprise diagnosis at 47, salon owner Christa Messmer found strength, faith and renewed meaning in life while facing colorectal cancer.

The FDA grants fast track status to alnodesertib plus low-dose irinotecan for third-line metastatic colorectal cancer with ATM deficiency.

Colorectal cancer is a complex disease. Understanding its fundamental aspects can empower you to have more informed and productive conversations with your oncologist.

Rising colorectal cancer rates in younger adults are prompting earlier screenings, with colonoscopy offering both detection and prevention.

How can colonoscopy detect colorectal cancer early and prevent it by removing polyps, compared with other noninvasive screening methods?

FDA grants D3S-001 treatment breakthrough therapy for KRAS G12C some with lung cancer and orphan drug status for KRAS G12C colorectal cancer in adults.

The FDA granted breakthrough device designation to Quest Diagnostics’ Haystack MRD test for patients with stage 2 colorectal cancer after surgery.

An off-the-shelf cancer vaccine is associated with durable responses and a reduced risk of relapse and death among patients with pancreatic or colorectal cancers.

The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency.

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic colorectal cancer to begin.

Writing helped me focus on gratitude and healing after my colon cancer diagnosis, transforming the act into a powerful recovery tool.

Three of five patients with advanced colorectal cancer responded to leronlimab, including one complete response lasting five years, according to new data.

The Colorectal Cancer Alliance initiative is bridging gaps in cancer care progress with grants totaling almost $12 Million.

Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic colorectal cancer, phase 3 data show.

Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.

Alliance survey reveals most Americans deprioritize colorectal cancer screening, yet screening & innovative research are critical to survivorship.

Braftovi and Erbitux plus chemotherapy improved survival without progression over standard therapy in BRAF V600E-mutant mCRC in the first-line setting.

Tumors shrank more with the addition of acoustic cluster therapy to chemotherapy in colorectal liver metastases in the phase 1 ACTIVATE trial.

As a Lynch syndrome previvor, I feel deep gratitude to witness my son’s graduation — a milestone my brother never lived to see with his own child.